New Stem Cell Models to Address Biological Complexity of ALS

The ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience have launched the Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modeling (PRISM) initiative, aimed at expanding access to patient-derived stem cell models. This collaborative effort is particularly significant as ALS is a heterogeneous disease, with 10-15% of cases linked to inherited mutations and nearly 85% classified as sporadic. According to a PRISM ALS official, the reliance on models representing a limited number of rare genetic subtypes has constrained target discovery and contributed to the high failure rate of clinical trials.

The PRISM initiative seeks to provide a high-quality, accessible source of sporadic ALS models for research. By developing and evaluating a diverse panel of well-characterized, patient-derived iPSC models, the initiative aims to capture both genetic and sporadic forms of ALS. For researchers and drug developers, these standardized models will enhance the understanding of disease mechanisms and facilitate the identification of therapeutic targets, ultimately leading to treatments that are more relevant to patients’ unique biological profiles.

Samples for the stem cells used in PRISM ALS are contributed by individuals living with ALS through ALS TDI’s ALS Research Collaborative (ARC) Study, the longest-running longitudinal patient study in ALS. As Fernando Vieira, MD, CEO and CSO of ALS TDI, notes, delivering the right treatments to the right individuals is crucial for ending ALS. The collaboration aims to leverage real-world variability across age, sex, and genotype to improve drug discovery outcomes. The hope is that these new stem cell models will catalyze the development of effective therapies that slow disease progression and ultimately lead to a cure for ALS.